IDH1 and central nervous system cancer: Using the EPIC methylation array, which is a more robust array covering > 850,000 CpG sites, and a discovery cohort of 39 glioma tissue samples, we successfully developed a DNA methylation (CIMP) signature to specifically distinguish IDH1/IDH2-positive samples from IDH1/IDH2-negative samples.